Galderma Group AG (GDERF) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Galderma Group AG $111, price $205, upside -45.8%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Galderma Group AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
29‑month range $76.26 – $245.97 · fair‑value band $79.66 – $143.14 · the $205.48 price screens above the $111.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Galderma Group in your weekly email
Every Wednesday you see whether Galderma Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology.
Show more
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Stock analysis
Galderma Group AG (GDERF) currently trades at $205.48, while our model-based Fair Value estimate is $111.40, implying the stock looks roughly 84.5% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $73.24 per share, and 0 of the 26 models we run sit above the $205.48 price.
Bear case: the Asset-Based group reads lowest at $23.28, and 26 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: $79.66 (bear) to $143.14 (bull), the price of $205.48 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Galderma Group AG reported revenue of $5.2B in FY2025 versus $3.4B in FY2021, a compound +11.1%/yr. Reported net income was $613M in FY2025.
Key figures
Market cap $48.2B · P/E ratio 79.6 · P/S ratio 9.32 · EPS (TTM) $2.58 · Dividend yield 0.2% · Net margin 11.7% · Return on equity 7.7% · Return on assets (EBIT) 5.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 23% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −46%, GDERF screens richer than that median.
Fair Value models
Bear $79.66Fair Value $111.40Bull $143.14
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($1.56 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.88/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+18.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.1%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
10.4% (2021) → 16.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+24.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+15.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +22.0% a year for the price and +13.1% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside−46% · Below median
Profitability
Return on equity (TTM)8% · Above median
Return on assets4% · Above median
Net margin (TTM)12% · Above median
Operating margin (TTM)18% · Top 25%
Growth and dividend
Revenue growth25% · Top 25%
Dividend yield (TTM)0.2% · Bottom 25%
Balance sheet
Debt / equity0.32× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)79.6× · Priciest 25%
P/B5.91× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)9.20× · Priciest 25%
P/FCF46.7× · Priciest 25%
EV/EBITDA44.1× · Priciest 25%
PEG1.88× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)100· sector 21
PAST (return on equity)31· sector 27
HEALTH (low debt)84· sector 96
DIVIDEND (yield)4· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Galderma Group AG Fair Value". https://www.fairvalue-calculator.com/stock/GDERF
Frequently asked questions
Is Galderma Group AG (GDERF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $111.40 versus a price of $205.48, about −46% upside (overvalued).
What is the fair value of GDERF?
Our model-based fair value for Galderma Group AG is $111.40 (as of Sep 24, 2026), built from audited fundamentals. The current price: $205.48.
What is the quality score of GDERF?
Galderma Group AG has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Galderma Group AG (GDERF)?
Our model-based price target is the fair value of $111.40 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario $79.66, optimistic scenario $143.14. It is a calculation from audited fundamentals, not an analyst target.
What is the Galderma Group AG stock forecast for 2026?
Our models put fair value at $111.40, about −46% upside versus a price of $205.48 (overvalued). Cautious scenario $79.66, optimistic scenario $143.14. The calculation is refreshed regularly with new filings.
What is the revenue of Galderma Group AG (GDERF)?
Galderma Group AG reported trailing-twelve-month revenue of about $5.2B (latest available figure, as of Sep 24, 2026).
Does Galderma Group AG pay a dividend?
Galderma Group AG currently shows a dividend yield of about 0.21% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Galderma Group AG (GDERF)?
For today's price to be fair in a discounted-cash-flow model, Galderma Group AG would have to grow free cash flow by +24.9 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +11.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of GDERF use?
Our models discount Galderma Group AG at 9.2 %: a base by market capitalisation (large), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Galderma Group AG that is +24.9 % per year a year over ten years, using the same discount rate (9.2 %) and the same formula as our fair value.
How much growth has Galderma Group AG (GDERF) delivered so far?
Over the past 4 years revenue at Galderma Group AG grew +11.1 % a year. The price currently implies +24.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Galderma Group AG (GDERF) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Galderma Group AG (+24.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Galderma Group AG (GDERF)?
The free-cash-flow yield on the price is 2.14 %: that much free cash flow Galderma Group AG produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Galderma Group AG (GDERF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Galderma Group AG it is $111.40 per share (as of Sep 24, 2026), against a price of $205.48. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Galderma Group AG stock overvalued or undervalued in 2026?
As of Sep 24, 2026, GDERF trades above its calculated fair value: price $205.48, fair value $111.40, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GDERF?
No. The price is what the market pays today ($205.48); the fair value is what the company's own numbers justify ($111.40). For Galderma Group AG the two are $94.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is Galderma Group AG worth?
The market values Galderma Group AG at about $48.2B (market capitalisation, as of Sep 24, 2026). Per share that is $205.48; our models calculate a fair value of $111.40 per share.
What do the bullish and bearish scenarios say about GDERF?
Our models span a range for Galderma Group AG: cautious scenario $79.66, base $111.40, optimistic $143.14 per share (as of Sep 24, 2026, price $205.48). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GDERF?
Galderma Group AG trades at a price-to-earnings ratio of 79.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $111.40 is built from several models across several years. Other multiples: PEG 1.9, P/B 5.9, P/S 9.2, EV/EBITDA 44.1.
What is the PEG ratio of GDERF?
The PEG ratio of Galderma Group AG is 1.88 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Galderma Group AG (GDERF)?
Balance-sheet figures for Galderma Group AG (as of Sep 24, 2026): return on equity 7.7%, debt of 0.32 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is GDERF from its 52-week high?
Galderma Group AG trades at $205.48, about 16% below its 52-week high of $245.97 and 23% above the low of $166.64 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $111.40 is for.
Which stocks are comparable to Galderma Group AG?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Galderma Group AG stock attractive at the current price?
The data as of Sep 24, 2026: price $205.48, calculated fair value $111.40 (−46%), Quality Score 74/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GDERF calculated?
We run Galderma Group AG through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $111.40, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Galderma Group AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Galderma Group AG (GDERF)?
The closing price on Sep 23, 2026 was $205.48. Our model-based fair value is $111.40, about −46% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Galderma Group AG right now?
A high-quality business (quality 74/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case ($143.14). The favourable scenario is already priced in.
Key figures of Galderma Group AG
How large is the market capitalisation of Galderma Group AG (GDERF)?
The market capitalisation of Galderma Group AG is $48.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Galderma Group AG (GDERF)?
The price-to-sales ratio of Galderma Group AG is 9.32 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Galderma Group AG (GDERF)?
Earnings per share at Galderma Group AG are $2.58 (price ÷ EPS = P/E 79.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Galderma Group AG (GDERF)?
The dividend yield of Galderma Group AG is 0.2% (payout 17.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Galderma Group AG (GDERF)?
The net margin of Galderma Group AG is 11.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Galderma Group AG (GDERF)?
The return on equity (ROE) of Galderma Group AG is 7.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Galderma Group AG (GDERF)?
On an EBIT basis the return on assets of Galderma Group AG is 5.6% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Galderma Group AG (GDERF)?
The operating margin of Galderma Group AG is 17.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Galderma Group AG (GDERF)?
Revenue at Galderma Group AG is growing +24.8% versus a year earlier (3y avg +11.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Galderma Group AG (GDERF)?
Earnings per share at Galderma Group AG are growing +129% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Galderma Group AG (GDERF) carry?
The net debt of Galderma Group AG is $1.8B (fiscal year 2025, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Galderma Group AG in the live analysis
One click puts Galderma Group AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 24, 2026